4th Bacteriophage Therapy Summit

Memo

With increasing regulatory flexibility for phage-based applications, address critical questions to help your phage technologies advance through commercial development. Are you ready to gain the insights needed to radically transform your bacteriophage therapies into commercially viable products? Returning for its 4th year, the Bacteriophage Therapy Summit remains the comprehensive global forum providing you with a deeper understanding beyond basic science from multi-disciplinary experts around the world.View the full event guide here: https://ter.li/ym5d9t 2022 Agenda at a Glance: -Navigate clinical trial rationale, distribution effects of formulation on reaching infection sites, lessons learned from compassionate use trials, and the regulatory pathway for commercial development with the hottest insights from our 35+ expert speaker faculty -Hear from international organizations including the FDA, BiomX, Locus Bioscience, Felix Bioscience, Phagomed, PhagePro, Cytophage, Sciphage and unite with the phage community prioritizing human health and disease -Discuss strategies to weaponize phage therapies including lysins, genetic engineered and combination approaches to create new pathways for the treatment of infectious diseases, across 3 days of unparalleled, industry-centered content -Keep your company's interest in bacteriophage therapies up-to-date and aligned with the new breakthroughs beyond basic science and establish your pathway to commercialization in 2022 and beyond See our full speaker faculty, all agenda topics and our attending audience in our event brochure: https://ter.li/ym5d9t URLs:Tickets: https://go.evvnt.com/923318-2?pid=5569Brochure: https://go.evvnt.com/923318-3?pid=5569 Date and Time: On Mon, Feb 14, 22 ( 9:00 AM) - Wed, Feb 16, 22 ( 5:00 PM) Prices:Industry Rate - Early Bird 1 - Conference Only (save $500): USD 1599.00,Industry Rate - Early Bird 1 - Conference + Workshop (save $500): USD 1998.00,Academic Rate - Early Bird 1 - Conference Only (save $500): USD 1399.00,Industry Rate - Early Bird 1 - Conference + Workshop (save $500): USD 1698.00 Speakers: Bob Blasdel, Research Director, Vesale Pharma , Cara Fiore, Microbiologist, FDA Office of Vaccines Research and Review , Carrie Furr, Co-Founder and Chief Executive Officer, Bacteriophage and Drug Development Consultants , Chandrabali Ghose, Founder and Chief Executive Officer, Bioharmony Therapeutics , Chris Lis, Cofounder and Chief Technical Officer, Uniphage , Danish Malik, Reader Industrial Biology, Loughborough University , Edward Burd, Senior Vice President Regulatory Affairs, BiomX , Greg Merril, Chief Executive Officer, Adaptive Phage Therapeutics , Hannah Tuson, Director of Discovery, Locus Biosciences , Heather Fairhead, Chief Executive Officer, Phico Therapeutics , Hesham Abdelbary, Orthopaedic Surgeon, Ottawa Hospital , Iddo Weiner, Director and Head of Software, BiomX , Katrine Whiteson, Associate Professor and Co-Director, Department of Molecular Biology and Biochemistry UCI Microbiome Center , Lauren Richardson, Head of Communications and Operations, Felix Biotechnology, Lorenzo Corsini, Co-Founder and Chief Executive Officer, Phagomed , Mathias Middelboe, Professor Marine Biology, University of Copenhagen, Melissa Haines, NIHR Academic Clinician in Infectious Diseases and Medical Microbiology, University Hospitals of Leicester NHS Trust - University of Leicester, Mikael Skurnik, Professor – Bacteriology, University of Helsinki , Minmin Yen, Chief Executive Officer and Co-Founder, PhagePro , Natalie Ma, Head of Business Development, Felix Biotechnology Natasha Klaponski, PhD, Cytophage, Pierre Kyme, Senior Director Business Development, Armata Pharmaceuticals, Ran Nir Paz, Associate Professor and Senior Physician, Hadassah Hebrew University Hospital, Rebekah Dedrick, Research Associate, University of Pittsburgh, Ronen Hazan, Associate Professor and Principal Investigator, Institute of Biomedical and Oral Research (IBOR) of the Hebrew University, Sabrina Green, Director of Research and Development, Baylor, Saima Aslam, Associate Professor Division of Infectious Diseases and Global Public Health, iPATH, Steven Theriault, Chief Executive Officer, Cytophage , Tobi Nagel, Founder, Phages for Global Health , Ursela P. Guce Bigol, Supervising Science Research Specialist, Department of Science and Technology – Industrial Technology Development Institute , Vincent Fischetti, Professor and Head of Lab, The Rockefeller University Viviana Clavijo, Chief Executive Officer, Sciphage , Zemphira Alavidze, Medical Microbiologist, Phage Therapy Centre